This Is Too Hot For ReShape Lifesciences Inc. (NASDAQ: RSLS), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

As a NASDAQ listed company, RSLS falls under the Healthcare sector while operating within the Medical Devices industry segment. The current market capitalization of ReShape Lifesciences Inc. is $4.33M. A total of 0.74 million shares were traded on the day, compared to an average of 927.07K shares.

In the most recent transaction, STANKOVICH THOMAS sold 131 shares of RSLS for 0.27 per share on Oct 25 ’23. After the transaction, the Chief Financial Officer now owns 22,949 company shares. In a previous transaction on Oct 11 ’23, STANKOVICH THOMAS sold 39 shares at 0.93 per share. RSLS shares that Chief Financial Officer owns now total 23,080.

Among the insiders who sold shares, STANKOVICH THOMAS disposed of 118 shares on Sep 01 ’23 at a per-share price of $0.89. This resulted in the Chief Financial Officer holding 23,119 shares of RSLS after the transaction. In another insider transaction, STANKOVICH THOMAS sold 39 shares at $1.42 per share on Aug 24 ’23. Company shares held by the Chief Financial Officer now total 23,237.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, RSLS has a high of $4.10 and a low of $0.14.

As of this writing, RSLS has an earnings estimate of -$0.18 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.18 per share and a lower estimate of -$0.18. The company reported an EPS of -$1.08 in the last quarter, which was 39.70% higher than expectations of -$1.79.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. RSLS’s latest balance sheet shows that the firm has $22.77M in Cash & Short Term Investments as of fiscal 2021. There were $279.00k in debt and $7.53M in liabilities at the time. Its Book Value Per Share was $0.89, while its Total Shareholder’s Equity was $44.33M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RSLS is Buy with a score of 5.00.

Most Popular

Related Posts